https://larcg.org/nefractomia-radical-laparoscopica-trans-e-retroperitoneal/ 2020-10-05T20:50:14+00:00 monthly 0.2 https://larcg.org/nefrectomia-parcial-laparoscopica-nova-tecnica/ 2020-10-05T20:49:56+00:00 monthly 0.2 https://larcg.org/informacion-sobre-el-cancer-de-rinon/ 2020-10-05T20:49:33+00:00 monthly 0.2 https://larcg.org/alternativas-de-control-precoz-de-la-arteria-renal-nefrectomia-radial-laparoscopica/ 2020-10-05T20:49:13+00:00 monthly 0.2 https://larcg.org/completely-endophytic-renal-tumor-a-laparoscopic-approach/ 2020-10-05T20:49:00+00:00 monthly 0.2 https://larcg.org/right-partial-nephrectomy-6cm/ 2020-10-05T20:48:47+00:00 monthly 0.2 https://larcg.org/iv-annual-larcg-meeting-at-aua-congress-san-francisco-2018/ 2020-10-05T20:48:35+00:00 monthly 0.2 https://larcg.org/circulating-fibroblast-growth-factor-21-fgf21-as-diagnostic-and-prognostic-biomarker-in-renal-cancer/ 2020-10-05T21:35:41+00:00 monthly 0.2 https://larcg.org/es/circulating-fibroblast-growth-factor-21-fgf21-as-diagnostic-and-prognostic-biomarker-in-renal-cancer-2/ 2020-10-05T21:37:30+00:00 monthly 0.2 https://larcg.org/current-patterns-of-presentation-and-treatment-of-renal-masses-a-clinical-research-office-of-the-endourological-society-prospective-study/ 2020-10-05T21:35:41+00:00 monthly 0.2 https://larcg.org/es/current-patterns-of-presentation-and-treatment-of-renal-masses-a-clinical-research-office-of-the-endourological-society-prospective-study-2/ 2020-10-05T21:37:30+00:00 monthly 0.2 https://larcg.org/interdisciplinary-management-of-renal-cell-carcinoma-associated-to-von-hippel-lindau-disease/ 2020-10-05T21:35:40+00:00 monthly 0.2 https://larcg.org/es/interdisciplinary-management-of-renal-cell-carcinoma-associated-to-von-hippel-lindau-disease-2/ 2020-10-05T21:37:30+00:00 monthly 0.2 https://larcg.org/renal-transplantation-management-of-renal-tumor-in-the-graft-and-in-the-native-kidney/ 2020-10-05T21:35:40+00:00 monthly 0.2 https://larcg.org/es/renal-transplantation-management-of-renal-tumor-in-the-graft-and-in-the-native-kidney-2/ 2020-10-05T21:37:30+00:00 monthly 0.2 https://larcg.org/positive-surgical-margins-are-predictors-of-local-recurrence-in-conservative-kidney-surgery-for-pt1-tumors/ 2020-10-05T21:35:40+00:00 monthly 0.2 https://larcg.org/es/positive-surgical-margins-are-predictors-of-local-recurrence-in-conservative-kidney-surgery-for-pt1-tumors-2/ 2020-10-05T21:37:30+00:00 monthly 0.2 https://larcg.org/american-confederation-of-urology-cau-experience-in-minimally-invasive-partial-nephrectomy/ 2020-10-05T21:35:40+00:00 monthly 0.2 https://larcg.org/es/american-confederation-of-urology-cau-experience-in-minimally-invasive-partial-nephrectomy-2/ 2020-10-05T21:37:30+00:00 monthly 0.2 https://larcg.org/es/evolution-of-circulating-tumor-dna-profile-from-first-line-to-subsequent-therapy-in-metastatic-renal-cell-carcinoma-2/ 2020-10-05T21:37:30+00:00 monthly 0.2 https://larcg.org/evolution-of-circulating-tumor-dna-profile-from-first-line-to-subsequent-therapy-in-metastatic-renal-cell-carcinoma/ 2020-10-05T21:35:40+00:00 monthly 0.2 https://larcg.org/es/comparative-effectiveness-of-initial-surgery-vs-initial-systemic-therapy-for-metastatic-kidney-cancer-in-the-targeted-therapy-era-analysis-of-a-population-based-cohort-2/ 2020-10-05T21:37:30+00:00 monthly 0.2 https://larcg.org/comparative-effectiveness-of-initial-surgery-vs-initial-systemic-therapy-for-metastatic-kidney-cancer-in-the-targeted-therapy-era-analysis-of-a-population-based-cohort/ 2020-10-05T21:35:40+00:00 monthly 0.2 https://larcg.org/es/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma-2/ 2020-10-05T21:37:30+00:00 monthly 0.2 https://larcg.org/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/ 2020-10-05T21:35:40+00:00 monthly 0.2 https://larcg.org/es/role-of-cytoreductive-nephrectomy-in-the-targeted-therapy-era-a-systematic-review-and-meta-analysis-2/ 2020-10-05T21:37:30+00:00 monthly 0.2 https://larcg.org/role-of-cytoreductive-nephrectomy-in-the-targeted-therapy-era-a-systematic-review-and-meta-analysis/ 2020-10-05T21:35:40+00:00 monthly 0.2 https://larcg.org/es/sunitinib-alone-or-after-nephrectomy-in-metastatic-renal-cell-carcinoma-2/ 2020-10-05T21:37:29+00:00 monthly 0.2 https://larcg.org/sunitinib-alone-or-after-nephrectomy-in-metastatic-renal-cell-carcinoma/ 2020-10-05T21:35:40+00:00 monthly 0.2 https://larcg.org/es/comparison-of-immediate-vs-deferred-cytoreductive-nephrectomy-in-patients-with-synchronous-metastatic-renal-cell-carcinoma-receiving-sunitinib-the-surtime-randomized-clinical-trial-2/ 2020-10-05T21:37:12+00:00 monthly 0.2 https://larcg.org/comparison-of-immediate-vs-deferred-cytoreductive-nephrectomy-in-patients-with-synchronous-metastatic-renal-cell-carcinoma-receiving-sunitinib-the-surtime-randomized-clinical-trial/ 2020-10-05T21:35:40+00:00 monthly 0.2 https://larcg.org/cytoreductive-nephrectomy-patient-selection-is-key/ 2020-10-05T21:35:16+00:00 monthly 0.2 https://larcg.org/cytoreductive-nephrectomy-questions-remain-after-carmena/ 2020-10-05T21:35:16+00:00 monthly 0.2 https://larcg.org/es/cytoreductive-nephrectomy-questions-remain-after-carmena-2/ 2020-10-05T21:37:12+00:00 monthly 0.2 https://larcg.org/es/cytoreductive-nephrectomy-patient-selection-is-key-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/es/nefractomia-radical-laparoscopica-trans-e-retroperitoneal-2/ 2020-10-05T20:41:02+00:00 monthly 0.2 https://larcg.org/es/nefrectomia-parcial-laparoscopica-nova-tecnica-2/ 2020-10-05T20:36:44+00:00 monthly 0.2 https://larcg.org/es/informacion-sobre-el-cancer-de-rinon-2/ 2020-10-05T20:36:29+00:00 monthly 0.2 https://larcg.org/es/alternativas-de-control-precoz-de-la-arteria-renal-nefrectomia-radial-laparoscopica-2/ 2020-10-05T20:35:40+00:00 monthly 0.2 https://larcg.org/es/completely-endophytic-renal-tumor-a-laparoscopic-approach-2/ 2020-10-05T20:35:25+00:00 monthly 0.2 https://larcg.org/es/right-partial-nephrectomy-6cm-2/ 2020-10-05T20:35:13+00:00 monthly 0.2 https://larcg.org/es/iv-annual-larcg-meeting-at-aua-congress-san-francisco-2018-2/ 2020-10-05T20:34:55+00:00 monthly 0.2 https://larcg.org/functional-and-oncologic-outcomes-after-nephron-sparing-surgery-in-a-solitary-kidney-10-years-of-experience-3/ 2020-10-05T21:35:16+00:00 monthly 0.2 https://larcg.org/es/functional-and-oncologic-outcomes-after-nephron-sparing-surgery-in-a-solitary-kidney-10-years-of-experience-3-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/renal-cryo/ 2020-10-05T20:34:10+00:00 monthly 0.2 https://larcg.org/es/renal-cryo-2/ 2020-10-05T20:33:52+00:00 monthly 0.2 https://larcg.org/tv-onconews-24-08-18/ 2020-10-05T20:33:40+00:00 monthly 0.2 https://larcg.org/es/tv-onconews-24-08-18-2-2/ 2020-10-05T20:33:27+00:00 monthly 0.2 https://larcg.org/larcg-at-the-seventeenth-international/ 2020-10-05T20:33:12+00:00 monthly 0.2 https://larcg.org/es/larcg-at-the-seventeenth-international-2/ 2020-10-05T20:32:57+00:00 monthly 0.2 https://larcg.org/es/nefrectomia-parcial-lumboscopica-sin-clampeo/ 2020-10-05T20:32:13+00:00 monthly 0.2 https://larcg.org/nefrectomia-parcial-lumboscopica-sin-clampeo-2/ 2020-10-05T20:31:55+00:00 monthly 0.2 https://larcg.org/the-creation-development-and-diffusion-of-the-larcg-latin-american-renal-cancer-group/ 2020-10-05T21:35:16+00:00 monthly 0.2 https://larcg.org/es/the-creation-development-and-diffusion-of-the-larcg-latin-american-renal-cancer-group-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/patient-reported-outcomes-of-patients-with-advanced-renal-cell-carcinoma-treated-with-nivolumab-plus-ipilimumab-versus-sunitinib-checkmate-214-a-randomised-phase-3-trial/ 2020-10-05T21:35:16+00:00 monthly 0.2 https://larcg.org/es/patient-reported-outcomes-of-patients-with-advanced-renal-cell-carcinoma-treated-with-nivolumab-plus-ipilimumab-versus-sunitinib-checkmate-214-a-randomised-phase-3-trial-es/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/caso-clinico-ha1/ 2020-10-05T20:27:25+00:00 monthly 1.0 https://larcg.org/es/caso-clinico-ha1-es/ 2020-10-05T20:27:01+00:00 monthly 0.2 https://larcg.org/combination-therapy-as-first-line-treatment-in-metastatic-renal-cell-carcinoma/ 2020-10-05T21:35:16+00:00 monthly 0.2 https://larcg.org/es/combination-therapy-as-first-line-treatment-in-metastatic-renal-cell-carcinoma-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/asco-gu-2019-gemcitabine-axitinib-shows-promising-efficacy-in-sarcomatoid-renal-cell-carcinoma/ 2020-10-05T21:35:16+00:00 monthly 0.2 https://larcg.org/es/asco-gu-2019-gemcitabine-axitinib-shows-promising-efficacy-in-sarcomatoid-renal-cell-carcinoma-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/ 2020-10-05T21:35:16+00:00 monthly 0.2 https://larcg.org/es/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/pembrolizumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/ 2020-10-05T21:35:16+00:00 monthly 0.2 https://larcg.org/es/pembrolizumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/change-in-neutrophil-to-lymphocyte-ratio-nlr-in-response-to-immune-checkpoint-blockade-for-metastatic-renal-cell-carcinoma/ 2020-10-05T21:35:15+00:00 monthly 0.2 https://larcg.org/es/change-in-neutrophil-to-lymphocyte-ratio-nlr-in-response-to-immune-checkpoint-blockade-for-metastatic-renal-cell-carcinoma-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/state-of-the-future-translational-approaches-in-renal-cell-carcinoma-in-the-immunotherapy-era/ 2020-10-05T21:35:15+00:00 monthly 0.2 https://larcg.org/es/state-of-the-future-translational-approaches-in-renal-cell-carcinoma-in-the-immunotherapy-era-es/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/cabozantinib-in-advanced-non-clear-cell-renal-cell-carcinoma-a-multicentre-retrospective-cohortstudy/ 2020-10-05T21:35:15+00:00 monthly 0.2 https://larcg.org/es/cabozantinib-in-advanced-non-clear-cell-renal-cell-carcinoma-a-multicentre-retrospective-cohortstudy-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/right-robotic-partial-nephrectomy-after-3d-reconstruction/ 2020-10-05T20:22:40+00:00 monthly 0.2 https://larcg.org/es/right-robotic-partial-nephrectomy-after-3d-reconstruction-2/ 2020-10-05T20:22:18+00:00 monthly 0.2 https://larcg.org/conditional-survival-of-patients-with-small-renal-masses-undergoing-active-surveillance/ 2020-10-05T21:35:15+00:00 monthly 0.2 https://larcg.org/es/conditional-survival-of-patients-with-small-renal-masses-undergoing-active-surveillance-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/partial-nephrectomy-vs-cryoablation-for-t1a-renal-cell-carcinoma-a-comparison-of-survival-benefit-stratified-by-tumour-size/ 2020-10-05T21:35:15+00:00 monthly 0.2 https://larcg.org/es/partial-nephrectomy-vs-cryoablation-for-t1a-renal-cell-carcinoma-a-comparison-of-survival-benefit-stratified-by-tumour-size-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/trifecta-outcomes-of-partial-nephrectomy-in-patients-over-75-years-old-analysis-of-the-renal-surgery-in-elderly-resurge-group/ 2020-10-05T21:35:15+00:00 monthly 0.2 https://larcg.org/es/trifecta-outcomes-of-partial-nephrectomy-in-patients-over-75-years-old-analysis-of-the-renal-surgery-in-elderly-resurge-group-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/selecting-patients-with-small-renal-masses-for-active-surveillance-a-domain-based-score-from-a-prospective-cohort-study/ 2020-10-05T21:35:15+00:00 monthly 0.2 https://larcg.org/es/selecting-patients-with-small-renal-masses-for-active-surveillance-a-domain-based-score-from-a-prospective-cohort-study-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/frequency-and-predictors-of-renal-transplantation-among-patients-rendered-surgically-anephric-for-sporadic-renal-cancer/ 2020-10-05T21:35:15+00:00 monthly 0.2 https://larcg.org/es/frequency-and-predictors-of-renal-transplantation-among-patients-rendered-surgically-anephric-for-sporadic-renal-cancer-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/es/predictive-value-of-single-nucleotide-polymorphism-signature-for-recurrence-in-localised-renal-cell-carcinoma-a-retrospective-analysis-and-multicentre-validation-study-2-2/ 2020-10-05T21:37:11+00:00 monthly 0.2 https://larcg.org/predictive-value-of-single-nucleotide-polymorphism-signature-for-recurrence-in-localised-renal-cell-carcinoma-a-retrospective-analysis-and-multicentre-validation-study-2-2-2/ 2020-10-05T21:35:15+00:00 monthly 0.2 https://larcg.org/predictive-value-of-single-nucleotide-polymorphism-signature-for-recurrence-in-localised-renal-cell-carcinoma-a-retrospective-analysis-and-multicentre-validation-study-2/ 2020-10-05T21:35:15+00:00 monthly 0.2 https://larcg.org/es/predictive-value-of-single-nucleotide-polymorphism-signature-for-recurrence-in-localised-renal-cell-carcinoma-a-retrospective-analysis-and-multicentre-validation-study-2-3/ 2020-10-05T21:37:10+00:00 monthly 0.2 https://larcg.org/systemic-therapy-in-the-management-of-localized-and-locally-advanced-renal-cell-carcinoma-current-state-and-future-perspectives/ 2020-10-05T21:35:14+00:00 monthly 0.2 https://larcg.org/es/systemic-therapy-in-the-management-of-localized-and-locally-advanced-renal-cell-carcinoma-current-state-and-future-perspectives-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/the-current-state-of-adjuvant-therapy-following-surgery-for-high-risk-renal-cell-carcinoma/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/the-current-state-of-adjuvant-therapy-following-surgery-for-high-risk-renal-cell-carcinoma-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/at-risk-kidney-how-surgical-factors-influence-renal-functional-preservation-after-partial-nephrectomy/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/at-risk-kidney-how-surgical-factors-influence-renal-functional-preservation-after-partial-nephrectomy-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/differential-expressions-of-pd-1-pd-l1-and-pd-l2-between-primary-and-metastatic-sites-in-renal-cell-carcinoma/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/differential-expressions-of-pd-1-pd-l1-and-pd-l2-between-primary-and-metastatic-sites-in-renal-cell-carcinoma-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/es/updated-european-association-of-urology-guidelines-on-renal-cell-carcinoma-immune-checkpoint-inhibition-is-the-new-backbone-in-first-line-treatment-of-metastatic-clear-cell-renal-cell-carcinoma/ 2020-10-05T19:26:39+00:00 monthly 0.2 https://larcg.org/updated-european-association-of-urology-guidelines-on-renal-cell-carcinoma-immune-checkpoint-inhibition-is-the-new-backbone-in-first-line-treatment-of-metastatic-clear-cell-renal-cell-carcinoma-2/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/treatment-related-adverse-events-of-pd-1-and-pd-l1-inhibitors-in-clinical-trials/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/treatment-related-adverse-events-of-pd-1-and-pd-l1-inhibitors-in-clinical-trials-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/es/valor-pronostico-de-la-invasion-de-grasa-perirrenal-y-o-del-seno-en-pacientes-con-carcinoma-de-celulas-renales-pt3a-estudio-de-cohorte-multicentrico-grupo-larcg/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/valor-pronostico-de-la-invasion-de-grasa-perirrenal-y-o-del-seno-en-pacientes-con-carcinoma-de-celulas-renales-pt3a-estudio-de-cohorte-multicentrico-grupo-larcg-2/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/safety-and-efficacy-of-nivolumab-in-patients-with-metastatic-renal-cell-carcinoma-and-end-stage-renal-disease-at-2-centers/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/safety-and-efficacy-of-nivolumab-in-patients-with-metastatic-renal-cell-carcinoma-and-end-stage-renal-disease-at-2-centers-2/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/predicting-renal-cancer-recurrence-defining-limitations-of-existing-prognostic-models-with-prospective-trial-based-validation/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/predicting-renal-cancer-recurrence-defining-limitations-of-existing-prognostic-models-with-prospective-trial-based-validation-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/clear-cell-renal-cell-carcinoma-molecular-characterization-of-imdc-risk-groups-and-sarcomatoid-tumors/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/clear-cell-renal-cell-carcinoma-molecular-characterization-of-imdc-risk-groups-and-sarcomatoid-tumors-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/renal-cell-cancer-treatment-an-expert-panel-recommendation-from-the-latin-american-cooperative-group-genitourinary-and-the-latin-american-renal-cancer-group-focus-on-surgery/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/renal-cell-cancer-treatment-an-expert-panel-recommendation-from-the-latin-american-cooperative-group-genitourinary-and-the-latin-american-renal-cancer-group-focus-on-surgery-2-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/surgical-safety-of-cytoreductive-nephrectomy-following-sunitinib-results-from-the-multicentre-randomised-controlled-trial-of-immediate-versus-deferred-nephrectomy-surtime/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/surgical-safety-of-cytoreductive-nephrectomy-following-sunitinib-results-from-the-multicentre-randomised-controlled-trial-of-immediate-versus-deferred-nephrectomy-surtime-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/adjuvant-therapy-in-patients-with-rcc/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/adjuvant-therapy-in-patients-with-rcc-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/rapid-deep-responses-with-nivolumab-plus-ipilimumab-in-papillary-renal-cell-carcinoma-with-sarcomatoid-dedifferentiation/ 2020-10-05T21:34:58+00:00 monthly 0.2 https://larcg.org/es/rapid-deep-responses-with-nivolumab-plus-ipilimumab-in-papillary-renal-cell-carcinoma-with-sarcomatoid-dedifferentiation-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/the-evolving-role-of-cytoreductive-nephrectomy-in-metastatic-renal-cell-carcinoma/ 2020-10-05T21:34:57+00:00 monthly 0.2 https://larcg.org/es/the-evolving-role-of-cytoreductive-nephrectomy-in-metastatic-renal-cell-carcinoma-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/is-cytoreductive-nephrectomy-relevant-in-the-immunotherapy-era/ 2020-10-05T21:34:57+00:00 monthly 0.2 https://larcg.org/es/is-cytoreductive-nephrectomy-relevant-in-the-immunotherapy-era-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/adjuvant-therapy-in-high-risk-renal-cell-cancer-a-systematic-review-and-meta-analysis/ 2020-10-05T21:34:57+00:00 monthly 0.2 https://larcg.org/es/adjuvant-therapy-in-high-risk-renal-cell-cancer-a-systematic-review-and-meta-analysis-2/ 2020-10-05T21:36:48+00:00 monthly 0.2 https://larcg.org/familial-kidney-cancer-implications-of-new-syndromes-and-molecular-insights/ 2020-10-05T21:34:57+00:00 monthly 0.2 https://larcg.org/es/familial-kidney-cancer-implications-of-new-syndromes-and-molecular-insights-2/ 2020-10-05T21:36:47+00:00 monthly 0.2 https://larcg.org/first-line-immuno-oncology-combination-therapies-in-metastatic-renal-cell-carcinoma-results-from-the-international-metastatic-renal-cell-carcinoma-database-consortium/ 2020-10-05T21:34:57+00:00 monthly 0.2 https://larcg.org/es/first-line-immuno-oncology-combination-therapies-in-metastatic-renal-cell-carcinoma-results-from-the-international-metastatic-renal-cell-carcinoma-database-consortium-2/ 2020-10-05T21:36:47+00:00 monthly 0.2 https://larcg.org/stereotactic-ablative-radiation-therapy-sabr-used-to-defer-systemic-therapy-in-oligometastatic-renal-cell-cancer/ 2020-10-05T21:34:57+00:00 monthly 0.2 https://larcg.org/es/stereotactic-ablative-radiation-therapy-sabr-used-to-defer-systemic-therapy-in-oligometastatic-renal-cell-cancer-2/ 2020-10-05T21:36:47+00:00 monthly 0.2 https://larcg.org/adjuvant-therapy-in-renal-cell-carcinoma/ 2020-10-05T21:34:57+00:00 monthly 0.2 https://larcg.org/es/adjuvant-therapy-in-renal-cell-carcinoma-2/ 2020-10-05T21:36:47+00:00 monthly 0.2 https://larcg.org/posicion-de-los-trocares-para-cirugia-laparoscopica-y-robotica-de-rinon-y-pelvica-de-acuerdo-a-la-anatomia-2/ 2020-10-05T18:58:30+00:00 monthly 0.2 https://larcg.org/long-noncoding-rna-lnc-dilc-stabilizes-pten-and-suppresses-clear-cell-renal-cell-carcinoma-progression/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/long-noncoding-rna-lnc-dilc-stabilizes-pten-and-suppresses-clear-cell-renal-cell-carcinoma-progression-2/ 2020-10-05T21:36:28+00:00 monthly 0.2 https://larcg.org/individualised-axitinib-regimen-for-patients-with-metastatic-renal-cell-carcinoma-after-treatment-with-checkpoint-inhibitors-a-multicentre-single-arm-phase-2-study/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/individualised-axitinib-regimen-for-patients-with-metastatic-renal-cell-carcinoma-after-treatment-with-checkpoint-inhibitors-a-multicentre-single-arm-phase-2-study-2/ 2020-10-05T21:36:28+00:00 monthly 0.2 https://larcg.org/renal-cell-carcinoma-treatment-after-first-line-combinations/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/renal-cell-carcinoma-treatment-after-first-line-combinations-2/ 2020-10-05T21:36:28+00:00 monthly 0.2 https://larcg.org/masas-renales-y-cancer-renal-localizado-guia-de-la-aua/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/masas-renales-y-cancer-renal-localizado-guia-de-la-aua-2/ 2020-10-05T21:36:28+00:00 monthly 0.2 https://larcg.org/atezolizumab-plus-bevacizumab-versus-sunitinib-in-patients-with-previously-untreated-metastatic-renal-cell-carcinoma-immotion151-a-multicentre-open-label-phase-3-randomised-controlled-trial/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/atezolizumab-plus-bevacizumab-versus-sunitinib-in-patients-with-previously-untreated-metastatic-renal-cell-carcinoma-immotion151-a-multicentre-open-label-phase-3-randomised-controlled-trial-2/ 2020-10-05T21:36:28+00:00 monthly 0.2 https://larcg.org/cytoreductive-nephrectomy-in-metastatic-papillary-renal-cell-carcinoma-results-from-the-international-metastatic-renal-cell-carcinoma-database-consortium/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/cytoreductive-nephrectomy-in-metastatic-papillary-renal-cell-carcinoma-results-from-the-international-metastatic-renal-cell-carcinoma-database-consortium-2/ 2020-10-05T21:36:28+00:00 monthly 0.2 https://larcg.org/__trashed/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/predictors-of-survival-outcomes-in-non-metastatic-renal-cell-carcinoma-in-latin-america-and-spain-a-multicentric-analysis/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/predictors-of-survival-outcomes-in-non-metastatic-renal-cell-carcinoma-in-latin-america-and-spain-a-multicentric-analysis-2/ 2020-10-05T21:36:28+00:00 monthly 0.2 https://larcg.org/es/the-evaluation-of-response-to-immunotherapy-in-metastatic-renal-cell-carcinoma-open-challenges-in-the-clinical-practice/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/pathologic-response-and-surgical-outcomes-in-patients-undergoing-nephrectomy-following-receipt-of-immune-checkpoint-inhibitors-for-renal-cell-carcinoma/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/pathologic-response-and-surgical-outcomes-in-patients-undergoing-nephrectomy-following-receipt-of-immune-checkpoint-inhibitors-for-renal-cell-carcinoma-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/complete-surgical-metastasectomy-for-renal-cell-carcinoma-in-the-post-cytokine-era/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/complete-surgical-metastasectomy-for-renal-cell-carcinoma-in-the-post-cytokine-era-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/validation-of-the-grade-age-nodes-and-tumor-grant-score-within-the-surveillance-epidemiology-and-end-results-seer-database-a-new-tool-to-predict-survival-in-surgically-treated-renal-cell-carcin/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/validation-of-the-grade-age-nodes-and-tumor-grant-score-within-the-surveillance-epidemiology-and-end-results-seer-database-a-new-tool-to-predict-survival-in-surgically-treated-renal-cell-carcin-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/prognostic-value-of-perirenal-and-or-sinus-fat-infiltration-in-patients-with-pt3a-renal-cell-carcinoma-a-multicentre-cohort-study-larcg-group/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/prognostic-value-of-perirenal-and-or-sinus-fat-infiltration-in-patients-with-pt3a-renal-cell-carcinoma-a-multicentre-cohort-study-larcg-group-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/sorafenib-versus-observation-following-radical-metastasectomy-for-clear-cell-renal-cell-carcinoma-results-from-the-phase-2-randomized-open-label-resort-study/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/sorafenib-versus-observation-following-radical-metastasectomy-for-clear-cell-renal-cell-carcinoma-results-from-the-phase-2-randomized-open-label-resort-study-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/the-impact-of-corticosteroid-use-during-anti-pd1-treatment/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/the-impact-of-corticosteroid-use-during-anti-pd1-treatment-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/first-line-systemic-therapy-for-metastatic-clear-cell-renal-cell-carcinoma-critical-appraisal-of-emerging-options/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/first-line-systemic-therapy-for-metastatic-clear-cell-renal-cell-carcinoma-critical-appraisal-of-emerging-options-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/prognostic-and-predictive-molecular-biomarkers-in-metastatic-renal-cell-carcinoma-patients-treatedwith-immune-checkpoint-inhibitors-a-systematic-review/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/prognostic-and-predictive-molecular-biomarkers-in-metastatic-renal-cell-carcinoma-patients-treatedwith-immune-checkpoint-inhibitors-a-systematic-review-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/impact-of-patients-gender-on-efficacy-of-immunotherapy-in-patients-with-metastatic-kidney-cancer-a-systematic-review-and-meta-analysis/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/impact-of-patients-gender-on-efficacy-of-immunotherapy-in-patients-with-metastatic-kidney-cancer-a-systematic-review-and-meta-analysis-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/a-pilot-study-of-radiation-therapy-in-combination-with-pembrolizumab-in-patients-with-metastatic-renal-cell-cancer/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/a-pilot-study-of-radiation-therapy-in-combination-with-pembrolizumab-in-patients-with-metastatic-renal-cell-cancer-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/management-of-renal-masses-and-localized-renal-cancer-systematic-review-and-meta-analysis/ 2020-10-05T21:34:34+00:00 monthly 0.2 https://larcg.org/es/management-of-renal-masses-and-localized-renal-cancer-systematic-review-and-meta-analysis-2/ 2020-10-05T21:36:27+00:00 monthly 0.2 https://larcg.org/predicting-renal-cancer-recurrence-defining-limitations-of-existing-prognostic-models-with-prospective-trial-based-validation-3/ 2020-10-05T21:34:33+00:00 monthly 0.2 https://larcg.org/es/predicting-renal-cancer-recurrence-defining-limitations-of-existing-prognostic-models-with-prospective-trial-based-validation-4/ 2020-10-05T21:36:26+00:00 monthly 0.2 https://larcg.org/first-line-immuno-oncology-combination-therapies-in-metastatic-renal-cell-carcinoma-resultsfrom-the-international-metastatic-renal-cell-carcinoma-database-consortium/ 2020-10-05T21:34:04+00:00 monthly 0.2 https://larcg.org/es/first-line-immuno-oncology-combination-therapies-in-metastatic-renal-cell-carcinoma-resultsfrom-the-international-metastatic-renal-cell-carcinoma-database-consortium-2/ 2020-10-05T21:36:03+00:00 monthly 0.2 https://larcg.org/prognostic-factors-in-de-novo-metastatic-renal-cell-carcinoma-a-report-from-the-latin-american-renal-cancer-group/ 2021-06-23T18:58:36+00:00 monthly 0.2 https://larcg.org/es/prognostic-factors-in-de-novo-metastatic-renal-cell-carcinoma-a-report-from-the-latin-american-renal-cancer-group-2/ 2021-06-23T18:58:12+00:00 monthly 0.2 https://larcg.org/non-contrast-imaging-characteristics-of-papillary-renal-cell-carcinoma-implications-for-diagnosisand-subtyping/ 2020-10-05T21:34:04+00:00 monthly 0.2 https://larcg.org/es/non-contrast-imaging-characteristics-of-papillary-renal-cell-carcinoma-implications-for-diagnosisand-subtyping-2/ 2020-10-05T21:36:03+00:00 monthly 0.2 https://larcg.org/perioperative-detection-of-circulating-tumor-cells-in-radical-or-partial-nephrectomy-for-renal-cell-carcinoma/ 2020-10-05T21:34:04+00:00 monthly 0.2 https://larcg.org/es/perioperative-detection-of-circulating-tumor-cells-in-radical-or-partial-nephrectomy-for-renal-cell-carcinoma-2/ 2020-10-05T21:36:03+00:00 monthly 0.2 https://larcg.org/long-term-survival-after-percutaneous-radiofrequency-ablation-of-pathologically-proven-renal-cell-carcinoma-in-100-patients/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/long-term-survival-after-percutaneous-radiofrequency-ablation-of-pathologically-proven-renal-cell-carcinoma-in-100-patients-2/ 2020-10-05T21:36:03+00:00 monthly 0.2 https://larcg.org/comparable-efficacy-and-safety-between-second-line-and-later-line-nivolumab-therapy-for-metastatic-renal-cell-carcinoma/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/comparable-efficacy-and-safety-between-second-line-and-later-line-nivolumab-therapy-for-metastatic-renal-cell-carcinoma-2/ 2020-10-05T21:36:03+00:00 monthly 0.2 https://larcg.org/long-term-risk-of-recurrence-in-surgically-treated-renal-cell-carcinoma-a-post-hoc-analysis-of-the-eastern-cooperative-oncology-group-american-college-of-radiology-imaging-network-e2805-trial/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/long-term-risk-of-recurrence-in-surgically-treated-renal-cell-carcinoma-a-post-hoc-analysis-of-the-eastern-cooperative-oncology-group-american-college-of-radiology-imaging-network-e2805-trial-2/ 2020-10-05T21:36:03+00:00 monthly 0.2 https://larcg.org/chronic-kidney-disease-and-kidney-cancer-surgery-new-perspectives/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/chronic-kidney-disease-and-kidney-cancer-surgery-new-perspectives-2/ 2020-10-05T21:36:03+00:00 monthly 0.2 https://larcg.org/impact-of-resection-technique-on-perioperative-outcomes-and-surgical-margins-after-partial-nephrectomy-for-localized-renal-masses-a-prospective-multicenter-study/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/impact-of-resection-technique-on-perioperative-outcomes-and-surgical-margins-after-partial-nephrectomy-for-localized-renal-masses-a-prospective-multicenter-study-2/ 2020-10-05T21:36:03+00:00 monthly 0.2 https://larcg.org/characteristics-and-surgical-outcomes-in-very-elderly-patients-%e2%89%a575-years-with-renal-cell-carcinoma-data-from-the-latin-american-renal-cancer-group/ 2021-06-23T18:37:37+00:00 monthly 0.2 https://larcg.org/es/characteristics-and-surgical-outcomes-in-very-elderly-patients-%e2%89%a575-years-with-renal-cell-carcinoma-data-from-the-latin-american-renal-cancer-group-2/ 2021-06-23T18:46:47+00:00 monthly 0.2 https://larcg.org/immunotherapy-based-combinations-versus-standard-first-line-treatment-for-metastatic-clear-cell-renal-cell-carcinoma-a-systematic-review-and-meta-analysis/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/immunotherapy-based-combinations-versus-standard-first-line-treatment-for-metastatic-clear-cell-renal-cell-carcinoma-a-systematic-review-and-meta-analysis-2/ 2020-10-05T21:36:03+00:00 monthly 0.2 https://larcg.org/deferred-cytoreductive-nephrectomy-following-presurgical-vascular-endothelial-growth-factor-receptor-targeted-therapy-in-patients-with-primary-metastatic-clear-cell-renal-cell-carcinoma-a-poo/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/deferred-cytoreductive-nephrectomy-following-presurgical-vascular-endothelial-growth-factor-receptor-targeted-therapy-in-patients-with-primary-metastatic-clear-cell-renal-cell-carcinoma-a-poo-2/ 2020-10-05T21:36:02+00:00 monthly 0.2 https://larcg.org/female-gender-predicts-favorable-prognosis-in-patients-with-non-metastatic-clear-cell-renal-cell-carcinoma-undergoing-curative-surgery-results-from-the-international-marker-consortium-for-renal-cance/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/female-gender-predicts-favorable-prognosis-in-patients-with-non-metastatic-clear-cell-renal-cell-carcinoma-undergoing-curative-surgery-results-from-the-international-marker-consortium-for-renal-canc-2/ 2020-10-05T21:36:02+00:00 monthly 0.2 https://larcg.org/construction-of-a-novel-gene-based-model-for-prognosis-prediction-of-clear-cell-renal-cell-carcinoma/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/construction-of-a-novel-gene-based-model-for-prognosis-prediction-of-clear-cell-renal-cell-carcinoma-2/ 2020-10-05T21:36:02+00:00 monthly 0.2 https://larcg.org/imdc-risk-calculator/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/imdc-risk-calculator-2/ 2020-10-05T21:36:02+00:00 monthly 0.2 https://larcg.org/small-renal-masses-in-latin-american-population-characteristics-and-prognostic-factors-for-survival-recurrence-and-metastasis-a-multi-institutional-study-from-larcg-database/ 2021-06-23T17:13:11+00:00 monthly 0.2 https://larcg.org/es/small-renal-masses-in-latin-american-population-characteristics-and-prognostic-factors-for-survival-recurrence-and-metastasis-a-multi-institutional-study-from-larcg-database-2/ 2021-06-23T17:14:21+00:00 monthly 0.2 https://larcg.org/consideration-in-the-management-of-renal-cell-carcinoma-during-the-covid-19-pandemic/ 2021-06-23T17:19:46+00:00 monthly 0.2 https://larcg.org/es/consideration-in-the-management-of-renal-cell-carcinoma-during-the-covid-19-pandemic-2/ 2023-09-06T14:19:56+00:00 monthly 0.2 https://larcg.org/electrocoagulation/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/electrocoagulation-with-greased-lidocaine-gel-2-as-hemostatic-maneuver-after-minimally-invasive-partial-nephrectomy-experimental-and-preliminary-clinical-results/ 2020-10-05T21:36:02+00:00 monthly 0.2 https://larcg.org/prognostic-value-of-histologic-subtype-and-treatment-modality-for-t1a-kidney-cancers/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/prognostic-value-of-histologic-subtype-and-treatment-modality-for-t1a-kidney-cancers-2/ 2020-10-05T21:36:02+00:00 monthly 0.2 https://larcg.org/compensatory-changes-in-parenchymal-mass-and-function-after-radical-nephrectomy/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/compensatory-changes-in-parenchymal-mass-and-function-after-radical-nephrectomy-2/ 2020-10-05T21:36:02+00:00 monthly 0.2 https://larcg.org/neutrophil-to-lymphocyte-ratio-as-a-prognostic-factor-of-disease-free-survival-in-postnephrectomy-high-risk-locoregional-renal-cell-carcinoma-analysis-of-the-s-trac-trial/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/neutrophil-to-lymphocyte-ratio-as-a-prognostic-factor-of-disease-free-survival-in-postnephrectomy-high-risk-locoregional-renal-cell-carcinoma-analysis-of-the-s-trac-trial-2/ 2020-10-05T21:36:02+00:00 monthly 0.2 https://larcg.org/tivozanib-in-renal-cell-carcinoma-a-new-approach-to-previously-treated-disease/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/tivozanib-in-renal-cell-carcinoma-a-new-approach-to-previously-treated-disease-2/ 2020-10-05T21:36:02+00:00 monthly 0.2 https://larcg.org/randomised-phase-ii-study-comparing-alternating-cycles-of-sunitinib-and-everolimus-vs-standard-sequential-administration-in-first-line-metastatic-renal-carcinoma-sunrises-study/ 2020-10-05T21:34:03+00:00 monthly 0.2 https://larcg.org/es/randomised-phase-ii-study-comparing-alternating-cycles-of-sunitinib-and-everolimus-vs-standard-sequential-administration-in-first-line-metastatic-renal-carcinoma-sunrises-study-2/ 2020-10-05T21:36:02+00:00 monthly 0.2 https://larcg.org/are-immune-checkpoint-inhibitors-a-valid-option-for-papillary-renal-cell-carcinoma-a-multicentre-retrospective-study/ 2020-10-05T21:34:02+00:00 monthly 0.2 https://larcg.org/es/are-immune-checkpoint-inhibitors-a-valid-option-for-papillary-renal-cell-carcinoma-a-multicentre-retrospective-study-2/ 2020-10-12T14:55:16+00:00 monthly 0.2 https://larcg.org/survival-outcomes-and-independent-response-assessment-with-nivolumab-plus-ipilimumab-versus-sunitinib-in-patients-with-advanced-renal-cell-carcinoma-42-month-follow-up-of-a-randomized-phase-3-clinica/ 2020-10-12T14:53:42+00:00 monthly 0.2 https://larcg.org/es/survival-outcomes-and-independent-response-assessment-with-nivolumab-plus-ipilimumab-versus-sunitinib-in-patients-with-advanced-renal-cell-carcinoma-42-month-follow-up-of-a-randomized-phase-3-clinic-2/ 2020-10-26T19:05:35+00:00 monthly 0.2 https://larcg.org/exposure-response-modeling-of-cabozantinib-in-patients-with-renal-cell-carcinoma-implications-for-patient-care/ 2020-10-19T15:59:08+00:00 monthly 0.2 https://larcg.org/es/exposure-response-modeling-of-cabozantinib-in-patients-with-renal-cell-carcinoma-implications-for-patient-care-2/ 2020-10-19T16:00:34+00:00 monthly 0.2 https://larcg.org/the-impact-of-bone-metastasis-location-in-the-clinical-outcome-of-patients-with-metastatic-renal-cell-carcinoma-mrcc-an-analysis-from-the-latin-american-renal-cancer-group-larcg/ 2021-06-22T20:00:10+00:00 monthly 0.2 https://larcg.org/es/the-impact-of-bone-metastasis-location-in-the-clinical-outcome-of-patients-with-metastatic-renal-cell-carcinoma-mrcc-an-analysis-from-the-latin-american-renal-cancer-group-larcg-2/ 2023-09-06T14:19:27+00:00 monthly 0.2 https://larcg.org/addition-of-primary-metastatic-site-on-bone-brain-and-liver-to-imdc-criteria-in-patients-with-metastatic-renal-cell-carcinoma-a-validation-study/ 2020-11-02T17:09:48+00:00 monthly 0.2 https://larcg.org/es/addition-of-primary-metastatic-site-on-bone-brain-and-liver-to-imdc-criteria-in-patients-with-metastatic-renal-cell-carcinoma-a-validation-study-2/ 2020-10-26T19:06:15+00:00 monthly 0.2 https://larcg.org/safety-and-efficacy-of-nivolumab-in-patients-with-advanced-clear-cell-renal-cell-carcinoma-results-from-the-phase-iiib-iv-checkmate-374-study/ 2020-11-02T17:07:33+00:00 monthly 0.2 https://larcg.org/es/safety-and-efficacy-of-nivolumab-in-patients-with-advanced-clear-cell-renal-cell-carcinoma-results-from-the-phase-iiib-iv-checkmate-374-study-2/ 2020-11-09T15:14:47+00:00 monthly 0.2 https://larcg.org/cabozantinib-after-a-previous-immune-checkpoint-inhibitor-in-metastatic-renal-cell-carcinoma-a-retrospective-multi-institutional-analysis/ 2020-11-16T14:51:03+00:00 monthly 0.2 https://larcg.org/es/cabozantinib-after-a-previous-immune-checkpoint-inhibitor-in-metastatic-renal-cell-carcinoma-a-retrospective-multi-institutional-analysis-2/ 2020-11-09T15:15:20+00:00 monthly 0.2 https://larcg.org/characterization-of-pd-1-and-pd-l1-expression-in-papillary-renal-cell-carcinoma-results-of-a-large-multicenter-study/ 2020-12-14T14:53:43+00:00 monthly 0.2 https://larcg.org/es/characterization-of-pd-1-and-pd-l1-expression-in-papillary-renal-cell-carcinoma-results-of-a-large-multicenter-study-2/ 2020-11-23T15:38:10+00:00 monthly 0.2 https://larcg.org/eau-2020-active-surveillance-proves-safe-and-noninferior-to-primary-intervention-for-small-renal-masses/ 2020-11-23T15:36:41+00:00 monthly 0.2 https://larcg.org/es/eau-2020-active-surveillance-proves-safe-and-noninferior-to-primary-intervention-for-small-renal-masses-2/ 2020-11-23T15:39:14+00:00 monthly 0.2 https://larcg.org/does-renal-tumor-biopsies-for-small-renal-carcinoma-increase-the-risk-of-upstaging-on-final-surgery-pathology-report-and-the-risk-of-recurrence/ 2020-12-21T14:33:04+00:00 monthly 0.2 https://larcg.org/es/does-renal-tumor-biopsies-for-small-renal-carcinoma-increase-the-risk-of-upstaging-on-final-surgery-pathology-report-and-the-risk-of-recurrence-2/ 2020-12-14T14:53:59+00:00 monthly 0.2 https://larcg.org/small-renal-mass-surveillance-histology-specific-growth-rates-in-a-biopsy-characterized-cohort/ 2020-12-21T14:38:27+00:00 monthly 0.2 https://larcg.org/es/small-renal-mass-surveillance-histology-specific-growth-rates-in-a-biopsy-characterized-cohort-2/ 2020-12-21T14:32:20+00:00 monthly 0.2 https://larcg.org/functional-and-oncological-outcome-of-percutaneous-cryoablation-versus-laparoscopic-partial-nephrectomy-for-clinical-t1-renal-tumors-a-propensity-score-matched-analysis/ 2020-12-28T16:25:51+00:00 monthly 0.2 https://larcg.org/es/functional-and-oncological-outcome-of-percutaneous-cryoablation-versus-laparoscopic-partial-nephrectomy-for-clinical-t1-renal-tumors-a-propensity-score-matched-analysis-2/ 2020-12-28T16:29:47+00:00 monthly 0.2 https://larcg.org/acute-interstitial-nephritis-a-potential-predictor-of-response-to-immune-checkpoint-inhibitors-in-renal-cell-carcinoma/ 2021-01-04T16:49:50+00:00 monthly 0.2 https://larcg.org/es/acute-interstitial-nephritis-a-potential-predictor-of-response-to-immune-checkpoint-inhibitors-in-renal-cell-carcinoma-2/ 2021-01-04T16:51:06+00:00 monthly 0.2 https://larcg.org/grading-chromophobe-renal-cell-carcinoma-evidence-for-a-four-tiered-classification-incorporating-coagulative-tumor-necrosis/ 2021-01-11T16:56:05+00:00 monthly 0.2 https://larcg.org/es/grading-chromophobe-renal-cell-carcinoma-evidence-for-a-four-tiered-classification-incorporating-coagulative-tumor-necrosis-2/ 2021-01-18T19:27:02+00:00 monthly 0.2 https://larcg.org/prognostic-molecular-signatures-for-metastatic-potential-in-clinically-low-risk-stage-i-and-ii-clear-cell-renal-cell-carcinomas/ 2021-01-18T19:24:42+00:00 monthly 0.2 https://larcg.org/es/prognostic-molecular-signatures-for-metastatic-potential-in-clinically-low-risk-stage-i-and-ii-clear-cell-renal-cell-carcinomas-2/ 2021-01-25T16:11:10+00:00 monthly 0.2 https://larcg.org/association-of-surgical-delay-and-overall-survival-in-patients-with-t2-renal-masses-implications-for-critical-clinical-decision-making-during-the-covid-19-pandemic/ 2021-01-25T16:09:39+00:00 monthly 0.2 https://larcg.org/es/association-of-surgical-delay-and-overall-survival-in-patients-with-t2-renal-masses-implications-for-critical-clinical-decision-making-during-the-covid-19-pandemic-2/ 2021-02-22T14:30:07+00:00 monthly 0.2 https://larcg.org/optimized-management-of-nivolumab-and-ipilimumab-in-advanced-renal-cell-carcinoma-a-response-based-phase-ii-study-omnivore/ 2021-02-08T14:39:18+00:00 monthly 0.2 https://larcg.org/es/optimized-management-of-nivolumab-and-ipilimumab-in-advanced-renal-cell-carcinoma-a-response-based-phase-ii-study-omnivore-2/ 2021-02-17T14:37:17+00:00 monthly 0.2 https://larcg.org/immune-related-adverse-events-in-advanced-kidney-cancer/ 2021-02-08T14:33:50+00:00 monthly 0.2 https://larcg.org/es/immune-related-adverse-events-in-advanced-kidney-cancer-2/ 2021-02-17T14:37:07+00:00 monthly 0.2 https://larcg.org/cytoreductive-nephrectomy-in-patients-presenting-with-advanced-disease-have-we-finally-answered-the-question/ 2021-02-17T14:35:14+00:00 monthly 0.2 https://larcg.org/es/cytoreductive-nephrectomy-in-patients-presenting-with-advanced-disease-have-we-finally-answered-the-question-2/ 2021-02-17T14:36:54+00:00 monthly 0.2 https://larcg.org/development-and-validation-of-a-clinical-prognostic-model-based-on-immune-related-genes-expressed-in-clear-cell-renal-cell-carcinoma/ 2021-02-22T14:29:01+00:00 monthly 0.2 https://larcg.org/es/development-and-validation-of-a-clinical-prognostic-model-based-on-immune-related-genes-expressed-in-clear-cell-renal-cell-carcinoma-2/ 2021-03-01T14:21:21+00:00 monthly 0.2 https://larcg.org/fear-of-cancer-recurrence-in-patients-with-localized-renal-cell-carcinoma/ 2021-03-08T14:52:19+00:00 monthly 0.2 https://larcg.org/es/fear-of-cancer-recurrence-in-patients-with-localized-renal-cell-carcinoma-2/ 2021-03-01T14:21:49+00:00 monthly 0.2 https://larcg.org/outcomes-of-complete-metastasectomy-in-metastatic-renal-cell-carcinoma-patients-the-canadian-kidney-cancer-information-system-experience/ 2021-03-08T14:50:10+00:00 monthly 0.2 https://larcg.org/es/outcomes-of-complete-metastasectomy-in-metastatic-renal-cell-carcinoma-patients-the-canadian-kidney-cancer-information-system-experience-2/ 2021-03-15T14:07:13+00:00 monthly 0.2 https://larcg.org/gender-differences-in-the-clinical-management-of-clinical-t1a-renal-cell-carcinoma/ 2021-03-15T14:05:38+00:00 monthly 0.2 https://larcg.org/es/gender-differences-in-the-clinical-management-of-clinical-t1a-renal-cell-carcinoma-2/ 2021-03-22T20:39:55+00:00 monthly 0.2 https://larcg.org/predictive-biomarkers-of-response-to-immunotherapy-in-metastatic-renal-cell-cancer/ 2021-04-05T14:34:21+00:00 monthly 0.2 https://larcg.org/es/predictive-biomarkers-of-response-to-immunotherapy-in-metastatic-renal-cell-cancer-2/ 2021-03-22T20:40:33+00:00 monthly 0.2 https://larcg.org/randomized-trial-assessing-impact-of-probiotic-supplementation-on-gut-microbiome-and-clinical-outcome-from-targeted-therapy-in-metastatic-renal-cell-carcinoma/ 2021-03-29T15:56:30+00:00 monthly 0.2 https://larcg.org/es/randomized-trial-assessing-impact-of-probiotic-supplementation-on-gut-microbiome-and-clinical-outcome-from-targeted-therapy-in-metastatic-renal-cell-carcinoma-2/ 2021-03-29T15:57:29+00:00 monthly 0.2 https://larcg.org/trends-in-initial-systemic-therapy-for-elderly-patients-with-metastatic-clear-cell-renal-cell-carcinoma/ 2021-04-05T14:30:34+00:00 monthly 0.2 https://larcg.org/es/trends-in-initial-systemic-therapy-for-elderly-patients-with-metastatic-clear-cell-renal-cell-carcinoma-2/ 2021-05-24T16:52:21+00:00 monthly 0.2 https://larcg.org/validation-of-the-grade-age-nodes-and-tumor-grant-score-within-the-surveillance-epidemiology-and-end-results-seer-database-a-new-tool-to-predict-survival-in-surgically-treated-renal-cell-carcin-3/ 2021-05-20T21:08:40+00:00 monthly 0.2 https://larcg.org/es/validation-of-the-grade-age-nodes-and-tumor-grant-score-within-the-surveillance-epidemiology-and-end-results-seer-database-a-new-tool-to-predict-survival-in-surgically-treated-renal-cell-carcin-4/ 2021-05-20T21:10:32+00:00 monthly 0.2 https://larcg.org/impact-of-clinicopathological-features-on-survival-in-patients-treated-with-first-line-immune-checkpoint-inhibitors-plus-tyrosine-kinase-inhibitors-for-renal-cell-carcinoma-a-meta-analysis-of-randomi/ 2021-05-31T14:21:36+00:00 monthly 0.2 https://larcg.org/es/impact-of-clinicopathological-features-on-survival-in-patients-treated-with-first-line-immune-checkpoint-inhibitors-plus-tyrosine-kinase-inhibitors-for-renal-cell-carcinoma-a-meta-analysis-of-random-2/ 2021-05-24T16:52:44+00:00 monthly 0.2 https://larcg.org/hypothermia-during-partial-nephrectomy-for-patients-with-renal-tumors-a-randomized-controlled-trial/ 2021-06-14T16:01:42+00:00 monthly 0.2 https://larcg.org/es/hypothermia-during-partial-nephrectomy-for-patients-with-renal-tumors-a-randomized-controlled-trial-2/ 2021-05-31T14:22:13+00:00 monthly 0.2 https://larcg.org/progressive-immune-dysfunction-with-advancing-disease-stage-in-renal-cell-carcinoma/ 2021-06-07T15:50:03+00:00 monthly 0.2 https://larcg.org/es/progressive-immune-dysfunction-with-advancing-disease-stage-in-renal-cell-carcinoma-2/ 2021-06-07T15:52:36+00:00 monthly 0.2 https://larcg.org/new-baseline-renal-function-after-radical-or-partial-nephrectomy-a-simple-and-accurate-predictive-model/ 2021-06-14T16:01:00+00:00 monthly 0.2 https://larcg.org/es/new-baseline-renal-function-after-radical-or-partial-nephrectomy-a-simple-and-accurate-predictive-model-2/ 2021-06-21T17:24:07+00:00 monthly 0.2 https://larcg.org/an-objective-assessment-of-performance-during-robotic-partial-nephrectomy-validation-and-correlation-of-automated-performance-metrics-with-intraoperative-outcomes/ 2021-06-21T17:18:50+00:00 monthly 0.2 https://larcg.org/es/an-objective-assessment-of-performance-during-robotic-partial-nephrectomy-validation-and-correlation-of-automated-performance-metrics-with-intraoperative-outcomes-2/ 2021-07-05T14:32:20+00:00 monthly 0.2 https://larcg.org/single-cell-sequencing-links-multiregional-immune-landscapes-and-tissue-resident-t-cells-in-ccrcc-to-tumor-topology-and-therapy-efficacy/ 2021-06-28T14:28:23+00:00 monthly 0.2 https://larcg.org/es/single-cell-sequencing-links-multiregional-immune-landscapes-and-tissue-resident-t-cells-in-ccrcc-to-tumor-topology-and-therapy-efficacy-2/ 2021-06-28T14:31:18+00:00 monthly 0.2 https://larcg.org/outcomes-of-active-surveillance-for-young-patients-with-small-renal-masses-prospective-data-from-the-dissrm-registry/ 2021-07-05T14:29:40+00:00 monthly 0.2 https://larcg.org/es/outcomes-of-active-surveillance-for-young-patients-with-small-renal-masses-prospective-data-from-the-dissrm-registry-2/ 2021-07-12T15:39:14+00:00 monthly 0.2 https://larcg.org/circulating-cytokines-associated-with-clinical-response-to-systemic-therapy-in-metastatic-renal-cell-carcinoma/ 2021-07-12T15:41:17+00:00 monthly 0.2 https://larcg.org/es/circulating-cytokines-associated-with-clinical-response-to-systemic-therapy-in-metastatic-renal-cell-carcinoma-2/ 2021-07-19T15:06:41+00:00 monthly 0.2 https://larcg.org/predicting-disease-recurrence-early-progression-and-overall-survival-following-surgical-resection-for-high-risk-localized-and-locally-advanced-renal-cell-carcinoma/ 2021-07-19T15:02:04+00:00 monthly 0.2 https://larcg.org/es/predicting-disease-recurrence-early-progression-and-overall-survival-following-surgical-resection-for-high-risk-localized-and-locally-advanced-renal-cell-carcinoma-2/ 2021-07-26T14:49:31+00:00 monthly 0.2 https://larcg.org/real-world-outcomes-in-patients-with-metastatic-renal-cell-carcinoma-according-to-risk-factors-the-star-tor-registry/ 2021-07-26T14:41:36+00:00 monthly 0.2 https://larcg.org/es/real-world-outcomes-in-patients-with-metastatic-renal-cell-carcinoma-according-to-risk-factors-the-star-tor-registry-2/ 2021-08-02T15:34:16+00:00 monthly 0.2 https://larcg.org/development-of-a-histopathology-informatics-pipeline-for-classification-and-prediction-of-clinical-outcomes-in-subtypes-of-renal-cell-carcinoma/ 2021-08-02T15:32:14+00:00 monthly 0.2 https://larcg.org/es/development-of-a-histopathology-informatics-pipeline-for-classification-and-prediction-of-clinical-outcomes-in-subtypes-of-renal-cell-carcinoma-2/ 2021-08-09T14:56:39+00:00 monthly 0.2 https://larcg.org/cytoreductive-nephrectomy-in-the-era-of-targeted-and-immuno-therapy-for-metastatic-renal-cell-carcinoma-an-elusive-issue-a-systematic-review-of-the-literature/ 2021-08-16T14:26:37+00:00 monthly 0.2 https://larcg.org/es/cytoreductive-nephrectomy-in-the-era-of-targeted-and-immuno-therapy-for-metastatic-renal-cell-carcinoma-an-elusive-issue-a-systematic-review-of-the-literature-2/ 2021-08-09T14:57:09+00:00 monthly 0.2 https://larcg.org/prognostic-effect-of-preoperative-serum-albumin-to-globulin-ratio-in-patients-treated-with-cytoreductive-nephrectomy-for-metastatic-renal-cell-carcinoma/ 2021-08-23T14:24:19+00:00 monthly 0.2 https://larcg.org/es/prognostic-effect-of-preoperative-serum-albumin-to-globulin-ratio-in-patients-treated-with-cytoreductive-nephrectomy-for-metastatic-renal-cell-carcinoma-2/ 2021-08-16T14:27:18+00:00 monthly 0.2 https://larcg.org/efficacy-of-immune-checkpoint-inhibitors-ici-in-the-treatment-of-older-adults-with-metastatic-renal-cell-carcinoma-mrcc-an-international-mrcc-database-consortium-imdc-analysis/ 2021-08-30T13:25:52+00:00 monthly 0.2 https://larcg.org/es/efficacy-of-immune-checkpoint-inhibitors-ici-in-the-treatment-of-older-adults-with-metastatic-renal-cell-carcinoma-mrcc-an-international-mrcc-database-consortium-imdc-analysis-2/ 2022-05-24T15:11:31+00:00 monthly 0.2 https://larcg.org/tumor-and-immune-reprogramming-during-immunotherapy-in-advanced-renal-cell-carcinoma/ 2021-08-30T13:24:16+00:00 monthly 0.2 https://larcg.org/es/tumor-and-immune-reprogramming-during-immunotherapy-in-advanced-renal-cell-carcinoma-2/ 2021-08-30T13:26:11+00:00 monthly 0.2 https://larcg.org/impact-of-body-mass-index-on-survival-outcomes-of-patients-with-metastatic-renal-cell-carcinoma-in-the-immuno-oncology-era-a-systematic-review-and-meta-analysis/ 2022-05-24T15:09:08+00:00 monthly 0.2 https://larcg.org/es/impact-of-body-mass-index-on-survival-outcomes-of-patients-with-metastatic-renal-cell-carcinoma-in-the-immuno-oncology-era-a-systematic-review-and-meta-analysis-2/ 2023-09-06T14:56:07+00:00 monthly 0.2 https://larcg.org/prognostic-factors-in-latin-american-patients-with-localized-and-advanced-renal-cell-carcinoma-a-literature-review/ 2023-09-06T14:57:02+00:00 monthly 0.2 https://larcg.org/es/prognostic-factors-in-latin-american-patients-with-localized-and-advanced-renal-cell-carcinoma-a-literature-review-2/ 2024-02-19T17:03:32+00:00 monthly 0.2 https://larcg.org/es/the-larcg-latin-american-renal-cancer-group-achievements-in-support-teaching-research-collaboration-and-advocacy/ 2024-02-19T17:04:19+00:00 monthly 0.2 https://larcg.org/the-larcg-latin-american-renal-cancer-group-achievements-in-support-teaching-research-collaboration-and-advocacy-2/ 2024-02-19T17:03:55+00:00 monthly 0.2 https://larcg.org/multi-ancestry-genome-wide-association-study-of-kidney-cancer-identifies-63-susceptibility-regions/ 2024-06-10T14:35:51+00:00 monthly 0.2 https://larcg.org/es/multi-ancestry-genome-wide-association-study-of-kidney-cancer-identifies-63-susceptibility-regions-2/ 2024-06-10T14:37:32+00:00 monthly 0.2